Liver Transplantation Avoided in Patients With Fulminant Hepatic Failure Who Received Albumin Dialysis With the Molecular Adsorbent Recirculating System While on the Waiting List: Impact of the Duration of Therapy

被引:27
作者
Camus, Christophe [1 ]
Lavoue, Sylvain [1 ]
Gacouin, Arnaud [1 ]
Compagnon, Philippe [2 ]
Boudjema, Karim [2 ]
Jacquelinet, Christian [3 ]
Thomas, Remi [1 ]
Le Tulzo, Yves [1 ]
机构
[1] Hop Pontchaillou, F-35033 Rennes 9, France
[2] CHRU, Pontchaillou Hosp, Dept Digest Surg, Rennes, France
[3] French Biomed Agcy, La Plaine St Denis, France
关键词
Fulminant hepatic failure; Liver transplantation; Molecular adsorbent recycling system albumin dialysis; BIOARTIFICIAL LIVER; BLOOD PURIFICATION; CONTROLLED-TRIAL; MARS; SUPPORT; COAGULATION; ACTIVATION;
D O I
10.1111/j.1744-9987.2009.00708.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Eighteen patients with fulminant hepatic failure due to various medical causes were listed for emergency liver transplantation and treated with extracorporeal albumin dialysis sessions using the molecular adsorbent recirculating system (MARS) at our center over a 74-month period. Due to improvement of liver function, transplantation could be avoided in 9 patients (50%, 95% confidence interval 29% to 71%) who fully recovered afterwards. This improvement rate was higher than the rate of improvement in the French cohort of fulminant hepatic failure patients with similar etiologies (19.3%, 95% confidence interval 14.9% to 24.6%, P = 0.002). In our 18 patients, there were no statistically significant differences in any baseline characteristics or in the time with liver failure meeting transplant criteria between the patients who improved while waiting and those who did not. However, the patients who improved received a greater number of sessions and a longer total duration of MARS therapy (all P < 0.001). In the whole study population, a MARS therapy duration >= 15 h was significantly associated with improvement of liver function without transplantation (adjusted adds ratio [OR] 65.76, 2.48-1743.11, P = 0.01). Tolerance of therapy was acceptable. These results suggest that MARS therapy could contribute to native liver recovery and is safe in patients on the waiting list for fulminant hepatic failure. A minimum duration of therapy (>= 15 h) could be necessary to expect significant liver function improvement.
引用
收藏
页码:549 / 555
页数:7
相关论文
共 35 条
[1]  
Awad SS, 1997, ASAIO J, V43, pM745
[2]   Results of a phase I trial evaluating a liver support device utilizing albumin dialysis [J].
Awad, SS ;
Swaniker, F ;
Magee, J ;
Punch, J ;
Bartlett, RH .
SURGERY, 2001, 130 (02) :354-362
[3]   Artificial liver support with the molecular adsorbent recirculating system:: activation of coagulation and bleeding complications [J].
Bachli, Esther B. ;
Schuepbach, Reto A. ;
Maggiorini, Marco ;
Stocker, Reto ;
Muellhaupt, Beat ;
Renner, Eberhard L. .
LIVER INTERNATIONAL, 2007, 27 (04) :475-484
[4]   Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study [J].
Bernal, W ;
Donaldson, N ;
Wyncoll, D ;
Wendon, J .
LANCET, 2002, 359 (9306) :558-563
[5]  
BERNUAU J, 1991, HEPATOLOGY, V14, pA49
[6]   ORTHOTOPIC LIVER-TRANSPLANTATION IN FULMINANT AND SUBFULMINANT HEPATITIS - THE PAUL-BROUSSE EXPERIENCE [J].
BISMUTH, H ;
SAMUEL, D ;
CASTAING, D ;
ADAM, R ;
SALIBA, F ;
JOHANN, M ;
AZOULAY, D ;
DUCOT, B ;
CHICHE, L .
ANNALS OF SURGERY, 1995, 222 (02) :109-119
[7]   Equipment review:: The molecular adsorbents recirculating system (MARS®) [J].
Boyle, M ;
Kurtovic, J ;
Bihari, D ;
Riordan, S ;
Steiner, C .
CRITICAL CARE, 2004, 8 (04) :280-286
[8]   Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation [J].
Camus, Christophe ;
Lavoue, Sylvain ;
Gacouin, Arnaud ;
Le Tulzo, Yves ;
Lorho, Richard ;
Boudjema, Karim ;
Jacquelinet, Christian ;
Thomas, Remi .
INTENSIVE CARE MEDICINE, 2006, 32 (11) :1817-1825
[9]   Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion [J].
Covic, A ;
Goldsmith, DJA ;
Gusbeth-Tatomir, P ;
Volovat, C ;
Dimitriu, AG ;
Cristogel, F ;
Bizo, A .
LIVER INTERNATIONAL, 2003, 23 :21-27
[10]   Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure [J].
Dabos, KJ ;
Newsome, PN ;
Parkinson, JA ;
Mohammed, HH ;
Sadler, IH ;
Plevris, JN ;
Hayes, PC .
TRANSPLANTATION, 2004, 77 (02) :200-205